Paradigm Biopharmaceuticals Limited (ASX:PAR)

Australia flag Australia · Delayed Price · Currency is AUD
0.615
+0.055 (9.82%)
Feb 21, 2025, 4:10 PM AEST
75.71%
Market Cap 239.50M
Revenue (ttm) n/a
Net Income (ttm) -58.65M
Shares Out 389.43M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,894,133
Average Volume 1,972,549
Open 0.545
Previous Close 0.560
Day's Range 0.545 - 0.635
52-Week Range 0.165 - 0.635
Beta 1.07
RSI 65.91
Earnings Date Feb 20, 2025

About ASX:PAR

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol PAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.